The article presents the author's comments on the research conducted by H. Lee and colleagues on the use of monoclonal antibodies against the human C5a receptor in complementary therapies for inflammation. According to the author, the strategy may find broader application in raising antibodies to cell-surface targets and facilitates more meaningful preclinical trials.